Drug eluting stent and braided wire for manufacturing a drug eluting stent

Abstract

The present application relates to a braided wire (10) for a drug eluting stent (100), characterized in that the braided wire defines a first inner lumen (20) and a second inner lumen (30) separated by a partition wall (40), the braided wire (10) further comprising a first passage (26) in fluid communication with the first inner lumen (20) to enable release of a first drug within the first inner lumen out of the braided wire (10) and a second passage (36) in fluid communication with the second inner lumen (30) to enable release of a second drug within the second inner lumen (30) out of the braided wire. The present application also relates to a drug eluting stent formed with the above braided wire.

Description

Technical Field

[0001] This application relates to the field of implantable medical device technology, specifically to a braided filament for a drug-eluting stent and a drug-eluting stent made from such a filament. Background Technology

[0002] Intracranial arteriosclerosis stenosis is one of the core causes of ischemic stroke, seriously threatening patients' lives, health, and quality of life. Current clinical treatments for this condition include intensive conservative treatment with medication and intracranial stent implantation. Among these, drug-eluting stents, with their continuous drug release characteristics, can effectively reduce the probability of restenosis after surgery and have gradually become the mainstream choice for interventional treatment of intracranial arterial stenosis.

[0003] Current intracranial drug-eluting stents generally employ a drug-polymer coating on the outer surface of the stent. Long-term clinical application has revealed that during the delivery and expansion of the target intracranial stenosis site, the drug coating on the stent is highly susceptible to abrasion against the vessel wall, leading to localized drug detachment. On one hand, detached drug particles may cause distal vessel embolism, increasing the risk of perioperative complications; on the other hand, this detachment results in insufficient drug delivery to the lesion area, failing to achieve the expected anti-intima-proliferative effect. Summary of the Invention

[0004] The purpose of this application is to provide a drug-eluting stent solution that solves the above-mentioned problems.

[0005] A first aspect of this application provides a braided filament for a drug-eluting stent, the braided filament defining a first inner cavity and a second inner cavity separated by a partition wall, the braided filament including a first inlet and a second inlet respectively leading to the first inner cavity and the second inner cavity for filling the first inner cavity and the second inner cavity with a first drug and a second drug respectively, the braided filament further including a first channel and a second channel respectively in fluid communication with the first inner cavity and the second inner cavity for releasing the first drug in the first inner cavity and the second drug in the second inner cavity from the braided filament respectively.

[0006] In some embodiments, the first and second cavities extend through the braided filaments along their entire length in the direction of extension.

[0007] In some embodiments, the first inner cavity is defined by the partition wall and a first filament wall portion of the braided yarn, the second inner cavity is defined by the partition wall and a second filament wall portion of the braided yarn, and the first channel and the second channel extend through the radial thickness of the first filament wall portion and the second filament wall portion, respectively.

[0008] In some embodiments, one or both of the first channel and the second channel include one or more orifices.

[0009] In some embodiments, the one or more openings include multiple rows of openings, each row of openings including a plurality of openings spaced apart along the extension direction of the braided yarn, in a circumferential direction surrounding the extension direction, or in an inclined direction inclined relative to the extension direction or the circumferential direction.

[0010] In some embodiments, one or both of the first channel and the second channel include one or more slits.

[0011] In some embodiments, the slit extends along the extension direction of the braided yarn, in a circumferential direction surrounding the extension direction, or in an inclined direction that is inclined relative to the extension direction or the circumferential direction.

[0012] In some embodiments, the cross-section of the first inner cavity and the second inner cavity perpendicular to the extension direction of the braided filament is one of a circle, an ellipse, a polygon, or an annulus.

[0013] In some embodiments, the braided yarn includes a constraint feature for preventing the braided yarn from twisting about its own axis during the braiding process.

[0014] In some embodiments, the constraint feature is at least one protrusion projecting from the outer surface of the braided yarn.

[0015] This application also relates to a drug-eluting stent, which is a tubular structure formed by weaving filaments and defines an internal space through which blood flow is permitted, wherein the filaments include the hollow filaments described above.

[0016] In some embodiments, the first and second cavities of the braided yarn are oriented toward and away from the internal space, respectively.

[0017] In some embodiments, the hollow filament includes a variety of different types of braided filaments, which differ in at least one of the following aspects: the shape and / or size of the first and second cavities, the structure of the first and second channels, and the material of the braided filaments.

[0018] In some embodiments, the filament material further includes one or more types of solid filament material.

[0019] The drug-eluting stent made using the braided wires of this application eliminates the need to apply therapeutic drugs to the outer surface of the stent, solving the problem of drug detachment inherent in traditional surface-coated stents and preventing complications such as distal vascular embolism. Using the drug-eluting stent of this application allows for precise control of drug dosage and reduces drug loss. Attached Figure Description

[0020] Figure 1 This is a perspective view of braided filaments for manufacturing a drug-eluting stent according to an exemplary embodiment of this application.

[0021] Figure 2 yes Figure 1 A cross-sectional view of the braided yarn.

[0022] Figure 3 yes Figure 1 A longitudinal cross-section of the braided yarn.

[0023] Figure 4 yes Figure 3 A magnified view of a portion of region A.

[0024] Figure 5 It is to utilize Figure 1 Drug-eluting scaffolds are formed by weaving filaments.

[0025] Figure 6 yes Figure 5 A schematic diagram of the cross-section of a drug-eluting stent.

[0026] Figure 7 yes Figure 6 A magnified view of a portion of region B.

[0027] Figure 8 It is a drug-eluting stent according to another embodiment corresponding to Figure 7 The view.

[0028] Figure 9 yes Figure 5-7 A schematic diagram of the cross-section of an intracranial drug-eluting stent immediately after implantation into a blood vessel.

[0029] Figure 10 yes Figure 5-7 A cross-sectional diagram of an intracranial drug-eluting stent implanted in a blood vessel 30-90 days after implantation.

[0030] Figure 11 This is a schematic diagram of braided yarn according to another embodiment. Detailed Implementation

[0031] The specific embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.

[0032] refer to Figure 1-4 Different views of the braided filament 10 used to manufacture the drug-eluting scaffold are shown.

[0033] The braided filament 10 extends along the extension direction or longitudinal direction L and has a generally cylindrical outer contour. The braided filament 10 defines a first inner cavity 20 and a second inner cavity 30 spaced apart by a partition wall 40. The braided filament 10 also includes a first inlet and a second inlet leading to the first inner cavity 20 and the second inner cavity 30, respectively, for filling or introducing a first drug and a second drug into the first inner cavity 20 and the second inner cavity 30, respectively.

[0034] In the illustrated embodiment, the first inner cavity 20 and the second inner cavity 30 of the braided filament 10 extend through the entire length of the braided filament 10 along its extension direction L, so that the first inlet and the second inlet can be openings of the first inner cavity 20 and the second inner cavity 30 at the ends of the braided filament 10, respectively.

[0035] The first inner cavity 20 of the braided filament 10 is defined by a partition wall 40 and a first filament wall portion 25, and the second inner cavity 30 of the braided filament 10 is defined by the partition wall 40 and the second filament wall portion 35. A first channel 26 is formed on the first filament wall portion 25. The first channel 26 extends through the thickness of the first filament wall portion 25 (i.e., the dimension in the radial direction perpendicular to the longitudinal direction L) and is in fluid communication with the first inner cavity 20, allowing the fluid drug within the first inner cavity 20 to flow out or be released from the braided filament 10 through the first channel 26. The first channel 26 may extend through the first filament wall portion 25 generally in a radial direction perpendicular to the longitudinal direction L, or it may extend through the first filament wall portion 25 at an angle in the radial direction. The direction in which the first channel 26 extends through the first filament wall portion 25 can affect the rate at which the first drug is released from the first inner cavity 20.

[0036] A second channel 36 is formed on the second filament wall portion 35. The second channel 36 penetrates the thickness of the second filament wall portion 35 and is in fluid communication with the second inner cavity 30, so that the fluid drug in the second inner cavity 30 can flow out or be released from the braided filament 10 through the second channel 36. Similarly, the direction in which the second channel 36 extends through the second filament wall portion 35 can be radial or any other inclined direction.

[0037] In the illustrated embodiment, both the first channel 26 and the second channel 36 are in the form of an array of orifices. The first channel 26 and the second channel 36 respectively include an array of first orifices 28 and an array of second orifices 38. The array of first orifices 28 includes three rows of first orifices 28, each row including a plurality of first orifices 28 spaced apart along the longitudinal direction L. The array of second orifices 38 also includes three rows of second orifices 38, each row including a plurality of second orifices 38 spaced apart along the longitudinal direction L. The first orifices 28 may have the same diameter as the second orifices 38; optionally, they may be different. For example, as... Figure 2 As shown, the diameter of the first orifice 28 can be larger than the diameter of the second orifice 38.

[0038] Those skilled in the art will understand that, provided the function of allowing the fluid drug in the corresponding cavity to flow out of the braided filaments is achieved, the first channel 26 and the second channel 36 are not limited to the form of the orifice array shown in the figure. The shape, size, and arrangement of the orifices can be modified according to actual needs.

[0039] In some embodiments, the first channel 26 and the second channel 36 may also be configured as slits or an array of slits, the slits being elongated in a direction such as a longitudinal direction L, a circumferential direction around the longitudinal direction L, or any other direction (e.g., a spiral direction). The first channel 26 for releasing fluid medication in the first cavity 20 or the second channel 36 for releasing fluid medication in the second cavity 30 may also be configured as any combination of orifices and slits.

[0040] The first channel 26 and the second channel 36 can be configured in the same or different ways to obtain different rates at which fluid drugs flow out of or are released from the braided filament 10.

[0041] In the illustrated embodiment, the first cavity 20 and the second cavity 30 may have substantially the same cross-sectional dimensions (e.g., cross-section). However, depending on the actual demand for the first and second drugs or any other requirements, the first cavity 20 and the second cavity 30 may have different cross-sectional dimensions.

[0042] In some embodiments, the outer diameter of the braided filament 10 is between 0.06 and 0.1 mm, the first inner cavity 20 and the second inner cavity 30 are generally D-shaped as shown in the figure, the wall thickness of the first filament wall portion 25 and the second filament wall portion 35 is in the range of 0.01 to 0.03 mm, and the thickness of the partition wall 40 is in the range of 0.01 to 0.02 mm.

[0043] In some embodiments, the first inner cavity 20 and the second inner cavity 30 have a generally circular cross-section, and the diameter of the circular first inner cavity 20 and the second inner cavity 30 is in the range of 0.04-0.08 mm. In some embodiments, the first inner cavity 20 and the second inner cavity 30 may be annular cross-sections. The cross-sectional shape and / or dimensions of the first inner cavity 20 and the second inner cavity 30 may be the same or different.

[0044] In some embodiments, the diameters of the first aperture 28 and the second aperture 38, which serve as the first channel 26 and the second channel 36, are in the range of 0.001-0.005 mm.

[0045] Figure 5 A drug-eluting stent 100 is shown. The drug-eluting stent 100 is made of... Figure 1-4The braided filaments 10 are made into a tubular mesh support through a braiding process, and the mesh openings are typically diamond-shaped. The braided filaments 10 used to form the drug-eluting support 100 can be, but are not limited to, cobalt-chromium alloy wire, nickel-titanium alloy wire, or other polymer material wires with shape memory function.

[0046] In some embodiments, the drug-eluting stent 100 is a generally cylindrical tubular body. The drug-eluting stent 100 defines an internal space 50 through which blood flow is permitted. Figure 6 yes Figure 5 A cross-sectional view of the drug-eluting stent 100 is shown, with the cross-section perpendicular to the central axis X of the tubular mesh stent. In one embodiment, the diameter of the tubular drug-eluting stent 100 is in the range of 1.5-5.5 mm, preferably in the range of 2-5 mm; Figure 7 yes Figure 6 A partially enlarged view of region B shows a cross-section of the braided filament 10 in the drug-eluting stent 100. The drug-eluting stent 100 of this application is configured such that the first inner lumen 20 of the braided filament 10 always faces the internal space 50, and thus the first inner lumen 20 is configured to be filled with an anticoagulant. A first channel 26 is used to slowly release the anticoagulant into the blood flow passing through the internal space 50, thereby preventing thrombus formation. For example, anticoagulants include, but are not limited to, heparin, apixaban, rivaroxaban, and edoxaban.

[0047] The second lumen 30 in the braided wire 10 always faces the vessel wall, and thus the second lumen 30 is configured to be filled with an anti-intima-proliferative drug. The second channel 36 is used to allow the anti-intima-proliferative drug to be slowly released into the contacted vessel wall. For example, anti-intima-proliferative drugs include, but are not limited to, paclitaxel, sirolimus or rapamycin, zotalimus or everolimus, tacrolimus, and dexamethasone.

[0048] In some embodiments, anticoagulant drugs and anti-endometrial hyperplasia drugs are respectively filled into the first lumen 20 and the second lumen 30 in the form of polymer carriers and released to the lesion site via the first channel 26 and the second channel 36. The polymer carriers include, but are not limited to, polyvinylidene fluoride, poly(vinylidene fluoride-hexafluoropropylene) copolymer, polylactic acid, polycaprolactone, etc.

[0049] In some embodiments, the braided filaments 10 of the drug-eluting stent 100 are coated with a polymer coating (not shown). The polymer coating may be, but is not limited to, polyphosphocholine, Parylene C, and polybutyl methacrylate. The polymer coating acts as a physical and chemical barrier between the metallic stent and the biological environment (blood), which can reduce the risk of thrombosis.

[0050] This application provides a novel drug-eluting stent 100 that utilizes the lumen provided by the braided wire itself to supply surgically required drugs to the lesion site and includes channels for slow drug release. As an example, the braided wire used to manufacture the drug-eluting stent 100 of this application provides two spaced-apart lumens capable of supplying two different drugs respectively. For instance, when the drug-eluting stent 100 is used for the treatment of intracranial atherosclerotic stenosis, the two lumens are respectively used to fill an anticoagulant and an anti-intima-proliferative drug.

[0051] Using the drug-eluting stent of this application, it is no longer necessary to coat the outer surface of the drug-eluting stent with a coating containing anticoagulants and anti-intima hyperplasia drugs. These drugs can be delivered inside the drug-eluting stent and can still inhibit intimal hyperplasia, prevent restenosis, and prevent thrombosis, thereby reducing perioperative complications.

[0052] Because it is not necessary to apply the drug to the outside of the stent, the drug-eluting stent of this application does not have the problem of drug detachment during the stent delivery to the target site or during drug release. All drugs are delivered entirely through the closed inner cavity of the braided wire, completely eliminating the risk of detachment of traditional surface drug coatings. It will not cause distal embolism due to drug particles, thus improving the safety of the procedure.

[0053] The braided wire provides two spaced-apart lumens, completely isolating the two drugs and preventing interference. The anticoagulant is released directionally only towards the internal space or towards the blood flow side, effectively inhibiting thrombus formation on the stent surface; the anti-intima-proliferative drug is released directionally only towards the vessel wall side, fully acting on the lesion area to inhibit smooth muscle proliferation. Therefore, the drug-eluting stent formed using the braided wire of this application effectively reduces the probability of restenosis, significantly shortens the treatment period of postoperative dual antiplatelet therapy, reduces the risk of bleeding, and results in better postoperative outcomes.

[0054] The drug in each lumen is slowly released through channels in the form of an array of orifices and / or slits (array). By designing various details of the two channels (orifices and / or slits, shape / size / interval or arrangement of orifices and / or slits, etc.), the drug release process or release rate can be effectively controlled, and the problem of local drug burst release that inhibits endothelial cell growth will not occur.

[0055] Figure 8 Similar to Figure 7 ,but Figure 8 The drug-eluting scaffold is constructed according to another embodiment of this application. Figure 8 The drug-eluting stent 100 is woven from at least two types of braided filaments 10 and 10′. Both filaments may be made of nickel-titanium alloy, but other materials or different materials may also be used.

[0056] 10 woven threads are as follows Figure 1-4 The hollow braided filament 10 shown has two cavities for the two drugs, while the braided filament 10' is a solid braided filament. Figure 5-7 The same embodiment is shown, with the braided filaments 10 oriented in the braided drug-eluting stent 100 as follows: the first lumen 20 for delivering anticoagulant drugs faces the internal space 50 of the stent and the second lumen 30 for delivering antiproliferative drugs faces the vascular intima.

[0057] All other things being equal, the drug-eluting stent of this embodiment is 100 times better than... Figure 5-7 Drug-eluting stents have a lower drug loading capacity, greater stent stiffness, lower flexibility, and greater radial support force on the vessel wall, in order to adapt to different design requirements and clinical needs.

[0058] As mentioned above, drug-eluting stents can utilize one or more of the following methods. Figure 1-4 The hollow braided yarn shown is one or more of the following. Figure 1-4 It is woven from a combination of hollow and solid braided yarns.

[0059] In some embodiments, drug-eluting stents may use only two or more types of drugs. Figure 1-4 The hollow braided yarns shown are woven together. Different types of hollow braided yarns differ in at least one parameter or aspect. In some specific examples, the different types of hollow braided yarns differ in the shape of at least one inner cavity, with the first type of hollow braided yarn having... Figure 1-4 The structure, the cross-sectional shape of the first inner cavity and the second inner cavity are D-shaped; the second type of hollow braided yarn has Figure 1-4 The structure is such that the cross-sections of the first and second inner cavities are circular. In some specific examples, different types of hollow braided yarns differ in the structure of at least one passage; the first type of double-cavity braided yarn has... Figure 1-4 The structure, the first passage and the second passage adopt an array structure of circular orifices as shown in the figure; the second type of hollow braided yarn has Figure 1-4 The structure, but at least one of the first and second passages is configured as one or more slits extending along the entire length of the braided filament. In some specific examples, different types of hollow braided filaments differ in the dimensions of at least one of the cavities, passages, etc.

[0060] In one embodiment, the drug-eluting stent can be formed using a combination of at least two types of hollow braided filaments and solid braided filaments as described above. The solid braided filaments may also include one type of solid braided filament, or multiple types of solid braided filaments with different shapes and / or sizes.

[0061] By selecting different combinations and configurations of hollow and solid braided wires, and by adjusting the characteristics (shape / size) of each lumen of each hollow braided wire and the characteristics of each channel used in each lumen, the drug loading capacity of the drug-eluting stent, the release rate of each drug, the overall stiffness of the stent, the radial or axial flexibility of the stent, the radial expandability of the stent, and the radial support force of the stent on the vessel wall can be flexibly adjusted or controlled. This allows the stent to be adapted to both calcified stenotic lesions requiring lower drug loading capacity and higher radial support force, and to tortuous intracranial vascular lesions requiring higher drug loading capacity and greater flexibility, thus covering more unmet clinical needs.

[0062] Figure 9 It shows Figure 5-7 The drug-eluting stent 100 is placed at the lesion site within a blood vessel V (the figure shows the intima layer V1 and the media layer V2). The figure shows that the first lumen 20 and the second lumen 30 of the stent 100 are oriented towards the internal space 50 of the stent and the blood vessel wall, respectively. A first drug M1 within the first lumen 20 can be directionally released into the blood flow within the internal space 50 via a first channel 26, and a second drug M2 within the second lumen 30 can be directionally released into the blood vessel wall via a second channel 36.

[0063] Figure 10 It shows Figure 5-7 This is a schematic diagram showing the drug-eluting stent 100 placed at the lesion site within blood vessel V for 30-90 days. The diagram shows that the first drug M1 in the first lumen 20 and the second drug M2 in the second lumen 30 have been largely or completely released. The drug-eluting stent 100 has completed the endothelialization process.

[0064] Figure 11 It shows Figure 1-4 A variant of the braided filament structure. Figure 11 Woven threads and Figure 2 The only difference between the braided yarns is that braided yarn 10 includes features for temporarily restraining braided yarn 10 during the weaving process into a support. Figure 11 This feature is shown as a protrusion 80 extending radially outward from the braided filament 10. During the braiding process, the protrusion 80, which restrains the braided filament 10, prevents the braided filament 10 from twisting about its own axis. In this way, it ensures that the lumen for anticoagulant drugs in any segment of the braided filament 10 in the formed drug-eluting stent 100 is oriented towards the internal space 50 of the stent, and the lumen for anti-intima-proliferative drugs is oriented towards the vessel wall. Those skilled in the art will understand that this feature is not essential and is not limited to the schematic structure shown in the figure.

[0065] After the braided body is formed by weaving the braided yarns, it needs to be heat-treated for shaping. Optionally, after the heat-treatment shaping, post-processing steps such as polishing the outer surface are also required. Optionally, after completing the above steps, the polymer coating is applied by ultrasonic spraying or electrochemical grafting to finally form the drug-eluting stent 100 of this application. In some embodiments, the polymer coating is applied by electrochemical graft polymerization of n-butyl methacrylate, and the coating thickness is 20-500 nm, more preferably 50-200 nm.

[0066] When the drug-eluting stent of this application is used to treat intracranial arteriosclerotic stenosis, the second lumen 30 of each hollow braided wire 10 is oriented towards the vascular intima. The anti-proliferative drug within the second lumen 30 diffuses or is released via the second channel 36 on the second wire wall portion 35, achieving the purpose of inhibiting smooth muscle proliferation. The first lumen 20 of the braided wire 10 is oriented towards the internal space 50 of the stent. The anticoagulant drug within the first lumen 20 diffuses or is released via the first channel 26 on the first wire wall portion 25, achieving the purpose of inhibiting thrombus formation. Endothelialization of the stent is essentially completed 30-90 days after implantation.

[0067] While ensuring the aforementioned functions are achieved, this application does not limit other details of the drug-eluting stent. For example, the stent can be formed by cross-weaving different braided filaments, or by cross-weaving two sections formed by bending the same braided filament.

[0068] The above description is only a preferred embodiment of the present invention. The scope of protection of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention.

Claims

1. A braided filament (10) for a drug-eluting stent (100), wherein, The braided filament defines a first cavity (20) and a second cavity (30) separated by a partition wall (40). The braided filament (10) also includes a first channel (26) in fluid communication with the first cavity (20) to allow a first drug in the first cavity to be released from the braided filament (10) and a second channel (36) in fluid communication with the second cavity (30) to allow a second drug in the second cavity (30) to be released from the braided filament.

2. The braided yarn (10) according to claim 1, wherein, The first inner cavity (20) and the second inner cavity (30) extend through the braided filament (10) along its entire length in the direction of extension.

3. The braided yarn (10) according to claim 2, wherein, The first inner cavity (20) is defined by the partition wall (40) and the first filament wall portion (25) of the braided filament, and the second inner cavity (30) is defined by the partition wall (40) and the second filament wall portion (35) of the braided filament. The first channel (26) and the second channel (36) respectively penetrate the radial thickness of the first filament wall portion (25) and the second filament wall portion (35).

4. The braided yarn (10) according to claim 3, wherein, One or both of the first channel (26) and the second channel (36) include one or more openings.

5. The braided yarn (10) according to claim 4, wherein, The one or more orifices include multiple rows of orifices, each row of orifices including multiple orifices spaced apart along the extension direction of the braided filament (10), in a circumferential direction surrounding the extension direction, or in an inclined direction inclined relative to the extension direction or the circumferential direction.

6. The braided yarn (10) according to any one of claims 1-5, wherein, One or both of the first channel (26) and the second channel (36) include one or more slits.

7. The braided yarn (10) according to claim 6, characterized in that, The slit extends along the extension direction of the braided yarn, in a circumferential direction surrounding the extension direction, or in an inclined direction that is inclined relative to the extension direction or the circumferential direction.

8. The braided yarn (10) according to any one of claims 1-7, wherein, The cross-section of the first inner cavity (20) and the second inner cavity (30) perpendicular to the extension direction of the braided yarn is one of a circle, an ellipse, a polygon, or an annulus.

9. The braided yarn (10) according to any one of claims 1-8, wherein, The braided yarn includes a constraint feature for preventing the braided yarn from twisting about its own axis during the braiding process.

10. The braided yarn (10) according to claim 9, wherein, The constraint feature is at least one protrusion that protrudes from the outer surface of the braided yarn.

11. A drug-eluting stent (100), said drug-eluting stent being a tubular structure formed of woven filaments and defining an internal space (50) through which blood flow is permitted, wherein, The filament includes hollow filament, which is a braided filament (10) according to any one of claims 1-10.

12. The drug-eluting stent (100) according to claim 11, wherein, The first inner cavity (20) and the second inner cavity (30) of the braided yarn (10) are oriented toward and away from the internal space, respectively.

13. The drug-eluting stent (100) according to claim 12, wherein, The hollow filament includes various types of braided filaments (10), which differ in at least one of the following aspects: the shape and / or size of the first inner cavity (20) and the second inner cavity (30), the structure of the first channel (26) and the second channel (36), and the material of the braided filaments.

14. The drug-eluting stent (100) according to any one of claims 11-13, wherein, The filament also includes one or more types of solid filament (10').

Images